KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Leases (2018 - 2025)

Vertex Pharmaceuticals has reported Operating Leases over the past 8 years, most recently at $1.8 billion for Q4 2025.

  • Quarterly results put Operating Leases at $1.8 billion for Q4 2025, up 13.18% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (up 13.18% YoY), and the annual figure for FY2025 was $1.8 billion, up 13.18%.
  • Operating Leases for Q4 2025 was $1.8 billion at Vertex Pharmaceuticals, up from $1.8 billion in the prior quarter.
  • Over the last five years, Operating Leases for VRTX hit a ceiling of $1.8 billion in Q4 2025 and a floor of $354.4 million in Q3 2023.
  • Median Operating Leases over the past 5 years was $382.0 million (2022), compared with a mean of $772.4 million.
  • Biggest five-year swings in Operating Leases: dropped 10.84% in 2023 and later surged 348.34% in 2024.
  • Vertex Pharmaceuticals' Operating Leases stood at $410.7 million in 2021, then grew by 4.24% to $428.1 million in 2022, then fell by 10.84% to $381.7 million in 2023, then surged by 327.43% to $1.6 billion in 2024, then increased by 13.18% to $1.8 billion in 2025.
  • The last three reported values for Operating Leases were $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.